First trade for 2021
This post was originally published on my old finance blog in January 2021. Transferred here as I am no longer maintaining that site.
As 2021 opened, I was looking for Covid-related stocks worth trading. After some research I settled on Atossa Genetics (ATOS) — a clinical-stage biopharmaceutical company with a Covid treatment in development.
I bought ATOS at $1.37 on 19th January. A week later, on 26th January, I sold half my position at $3.50 — just over a 2.5x return on that half.
The reason I only sold half was deliberate. By selling enough to recover my initial capital plus some profit, the remaining shares were effectively playing with house money. If the stock went to zero from that point, I would still be ahead overall. If it kept running, I had exposure.
I have never held a stock for more than a year. ATOS felt like the right candidate to start. The plan was to hold the remaining half for a long time — years, not months — and to be comfortable with losing it entirely if it came to that.
Not sure what the future holds for ATOS. But the discipline of separating house money from real money is something I want to apply more consistently going forward.
This is not financial advice. Just a record of one trade and the thinking behind it.
/ Comments